-
公开(公告)号：US20220226666A1
公开(公告)日：2022-07-21
申请号：US17655683
申请日：2022-03-21
申请人： IMMUNOLIGHT, LLC , DUKE UNIVERSITY
发明人： Mark Oldham , Zakaryae Fathi , Wayne F. Beyer , Frederic A. Bourke, JR. , Harold Walder , Mark Dewhirst , Neil L. Spector , Paul Yoon , Justus Adamson , David Alcorta , Kim Lyerly , Leihua Liu , Takuya Osada
IPC分类号： A61N5/06 , A61K31/352 , A61K41/00
摘要： A method for treating a diseased site in a human or animal body is provided which includes injecting in a diseased site one or more phosphors which are capable of emitting ultraviolet or visible light into the body;
infusing the diseased site with a photoactivatable drug;
applying an initiation energy from an initiation energy source comprising an x-ray, gamma ray, or electron source to thereby initiate emission of ultraviolet or visible light into the body; and
controlling a dose of the initiation energy with a processor to produce (i) a cytotoxicity inside the diseased site of greater than 20% or (ii) a day-25 stable tumor volume,
wherein the processor is programmed to apply the initiation energy in a pulsed manner, wherein the initiation energy is delivered in either (i) a radiograph mode, or (ii) a pulsed fluoroscopy mode.-
公开(公告)号：US11207409B2
公开(公告)日：2021-12-28
申请号：US15992852
申请日：2018-05-30
申请人： IMMUNOLIGHT, LLC , DUKE UNIVERSITY
发明人： Frederic A. Bourke, Jr. , Mark Dewhirst , Neil Spector , Paul Yoon , Justus Adamson , David Alcorta , Kim Lyerly , Leihua Liu , Takuya Osada , Mark Oldham , Zakaryae Fathi , Wayne F. Beyer , Harold Walder
摘要： A system (and associated method) for treating a human or animal body. The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carrier including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy into the body which activates the photoactivatable drug, a first device which infuses the first diseased site with a photoactivatable drug and the first pharmaceutically acceptable carrier, a first energy source which irradiates the diseased site with an initiation energy to thereby initiate emission of the activation energy into the body, and a supplemental treatment device which administers one or both of a therapeutic drug or radiation to the body at a second diseased site or the first diseased site, to provide an immune system stimulation in the body.
-
公开(公告)号：US11305131B2
公开(公告)日：2022-04-19
申请号：US16554831
申请日：2019-08-29
申请人： IMMUNOLIGHT, LLC , DUKE UNIVERSITY
发明人： Mark Oldham , Zakaryae Fathi , Wayne F. Beyer , Frederic A. Bourke, Jr. , Harold Walder , Mark DeWhirst , Neil L. Spector , Paul Yoon , Justus Adamson , David Alcorta , Kim Lyerly , Leihua Liu , Takuya Osada
IPC分类号： A61N5/06 , A61K41/00 , A61N5/10 , A61K31/352
摘要： A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.
-
公开(公告)号：US20180154178A1
公开(公告)日：2018-06-07
申请号：US15819130
申请日：2017-11-21
申请人： IMMUNOLIGHT, LLC. , DUKE UNIVERSITY
发明人： Mark Oldham , Justus Adamson , Paul Yoon , Harold Walder , Frederic A. Bourke, JR. , Zakaryae Fathi , Wayne F. Beyer
CPC分类号： A61N5/1031 , A61K31/37 , A61K41/0057 , A61K41/0066 , A61K49/0423 , A61N5/1077 , A61N2005/1034 , A61N2005/1098 , A61P35/00 , C09K11/02 , C09K11/595 , C09K11/73
摘要： A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug.
-
公开(公告)号：US11992697B2
公开(公告)日：2024-05-28
申请号：US17655683
申请日：2022-03-21
申请人： IMMUNOLIGHT, LLC , DUKE UNIVERSITY
发明人： Mark Oldham , Zakaryae Fathi , Wayne F. Beyer , Frederic A. Bourke, Jr. , Harold Walder , Mark Dewhirst , Neil L. Spector , Paul Yoon , Justus Adamson , David Alcorta , Kim Lyerly , Leihua Liu , Takuya Osada
IPC分类号： A61N5/06 , A61K31/352 , A61K41/00 , A61N5/10
CPC分类号： A61N5/062 , A61K31/352 , A61K41/0066 , A61N2005/0661 , A61N2005/0662 , A61N5/10 , A61N2005/1089 , A61N2005/1098
摘要： A method for treating a diseased site in a human or animal body is provided which includes injecting in a diseased site one or more phosphors which are capable of emitting ultraviolet or visible light into the body;
infusing the diseased site with a photoactivatable drug;
applying an initiation energy from an initiation energy source comprising an x-ray, gamma ray, or electron source to thereby initiate emission of ultraviolet or visible light into the body; and
controlling a dose of the initiation energy with a processor to produce (i) a cytotoxicity inside the diseased site of greater than 20% or (ii) a day-25 stable tumor volume,
wherein the processor is programmed to apply the initiation energy in a pulsed manner, wherein the initiation energy is delivered in either (i) a radiograph mode, or (ii) a pulsed fluoroscopy mode.-
公开(公告)号：US10940329B2
公开(公告)日：2021-03-09
申请号：US15819130
申请日：2017-11-21
申请人： IMMUNOLIGHT, LLC , DUKE UNIVERSITY
发明人： Mark Oldham , Justus Adamson , Paul Yoon , Harold Walder , Frederic A. Bourke, Jr. , Zakaryae Fathi , Wayne F. Beyer
IPC分类号： A61K49/00 , A61N5/10 , C09K11/59 , C09K11/73 , C09K11/02 , A61K31/37 , A61P35/00 , A61K41/00 , A61K49/04
摘要： A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug.
-
公开(公告)号：US10596387B2
公开(公告)日：2020-03-24
申请号：US15307766
申请日：2015-04-22
申请人： IMMUNOLIGHT, LLC. , DUKE UNIVERSITY
发明人： Harold Walder , Frederic A. Bourke , Zakaryae Fathi , Wayne F. Beyer , Mark W. Dewhirst , Mark Oldham , Justus Adamson , Michael Nolan
摘要： A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.
-
公开(公告)号：US10441810B2
公开(公告)日：2019-10-15
申请号：US15434871
申请日：2017-02-16
申请人： IMMUNOLIGHT, LLC , DUKE UNIVERSITY
发明人： Mark Oldham , Zakaryae Fathi , Wayne F. Beyer , Harold Walder , Frederic A. Bourke, Jr. , Mark Dewhirst , Neil L. Spector , Paul Yoon , Justus Adamson , David Alcorta , Kim Lyerly , Leihua Liu , Takuya Osada
IPC分类号： A61N5/06 , A61K41/00 , A61N5/10 , A61K31/352
摘要： A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.
-
公开(公告)号：US12121746B2
公开(公告)日：2024-10-22
申请号：US17433890
申请日：2020-01-30
申请人： IMMUNOLIGHT, LLC
发明人： Frederic A. Bourke, Jr. , Harold Walder , Zakaryae Fathi , Wayne F. Beyer , Ronald A. Rudder , Joseph H. Simmons
IPC分类号： A61N5/06 , A61K35/12 , A61K41/00 , A61N5/067 , C09J133/08 , C09K11/02 , C09K11/59 , C09K11/76 , C09K11/77 , C12N15/01 , F21K2/00 , F21S11/00 , F21V9/40 , H01J45/00 , H01L23/00 , H01L31/0352 , H01L31/054 , H01L31/06 , H01L31/055
CPC分类号： A61N5/0625 , A61K35/12 , A61K41/00 , A61K41/0057 , A61N5/0601 , A61N5/062 , A61N5/067 , C09J133/08 , C09K11/025 , C09K11/595 , C09K11/76 , C09K11/7701 , C09K11/7792 , C12N15/01 , F21K2/00 , F21S11/007 , F21V9/40 , H01J45/00 , H01L24/29 , H01L24/83 , H01L31/035281 , H01L31/054 , H01L31/06 , A61N2005/0661 , A61N2005/0662 , A61N2005/0663 , H01L31/055 , H01L2224/2919 , H01L2224/29393 , H01L2224/8322 , H01L2224/83855
摘要： An emission enhancement structure having at least one energy augmentation structure; and an energy converter capable of receiving energy from an energy source, converting the energy and emitting therefrom a light of a different energy than the received energy. The energy converter is disposed in a vicinity of the at least one energy augmentation structure such that the emitted light is emitted with an intensity larger than if the converter were remote from the at least one energy augmentation structure. Also described are various uses for the energy emitters, energy augmentation structures and energy collectors in a wide array of fields, particularly medical uses for treatment of cell proliferation disorders.
-
10.发明授权公开(公告)号：US11998760B2
公开(公告)日：2024-06-04
申请号：US17433827
申请日：2020-02-27
申请人： IMMUNOLIGHT, LLC
发明人： Frederic A. Bourke, Jr. , Harold Walder , Zakaryae Fathi , Wayne F. Beyer , Ronald A. Rudder , Daniel I. Becker , Joseph H. Simmons
IPC分类号： H01L31/044 , A61K35/12 , A61K41/00 , A61N5/06 , A61N5/067 , C09J133/08 , C09K11/02 , C09K11/59 , C09K11/76 , C09K11/77 , C12N15/01 , F21K2/00 , F21S11/00 , F21V9/40 , H01J45/00 , H01L23/00 , H01L31/0352 , H01L31/054 , H01L31/06 , H01L31/055
CPC分类号： A61N5/0625 , A61K35/12 , A61K41/00 , A61K41/0057 , A61N5/0601 , A61N5/062 , A61N5/067 , C09J133/08 , C09K11/025 , C09K11/595 , C09K11/76 , C09K11/7701 , C09K11/7792 , C12N15/01 , F21K2/00 , F21S11/007 , F21V9/40 , H01J45/00 , H01L24/29 , H01L24/83 , H01L31/035281 , H01L31/054 , H01L31/06 , A61N2005/0661 , A61N2005/0662 , A61N2005/0663 , H01L31/055 , H01L2224/2919 , H01L2224/29393 , H01L2224/8322 , H01L2224/83855
摘要： An emission enhancement structure having at least one energy augmentation structure; and an energy converter capable of receiving energy from an energy source, converting the energy and emitting therefrom a light of a different energy than the received energy. The energy converter is disposed in a vicinity of the at least one energy augmentation structure such that the emitted light is emitted with an intensity larger than if the converter were remote from the at least one energy augmentation structure. Also described are various uses for the energy emitters, energy augmentation structures and energy collectors in a wide array of fields, especially in the field of solar cells and other energy conversion devices.
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.026 秒)
